MiRNA Sequencing & Assay Market Size to Hit Around US$ 600.8 Bn by 2030

The global MiRNA Sequencing And Assay market size is expected to be worth around US$ 600.8 Mn by 2030, according to a new report by Vision Research Reports

The global MiRNA Sequencing And Assay market size was valued at US$ 224.8 Mn in 2020 and is anticipated to grow at a CAGR of 13.08% during forecast period 2021 to 2030.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38148

Growth Factors

Prominent players, such as Illumina, PerkinElmer, Qiagen, and others offer advanced miRNA sequencing products for multiple clinical applications. Moreover, these companies have collaborated with research institutes to expand the application of miRNA sequencing and assay in research studies.

The market holds a significant growth potential owing to the increasing application of miRNA sequencing and assay in the healthcare industry. For instance, several research studies demonstrate that miRNAs can be used as efficient biomarkers in the diagnosis and prognosis of cancer (breast, ovarian, cervical, and others), cardiovascular diseases, sepsis, and nervous system disorders. Therefore, miRNA sequence analysis is increasingly employed to analyze gene regulation in clinical disorders.

As plasma from COVID-19 recovered patients is rich in antiviral miRNAs and antibodies, it has been employed to treat SARS-CoV-2 infected patients. This has led to an increase in research studies that focus on the sequence analysis of miRNAs (microRNA) from the patient as well as the virus.

Scope of The Report

Report Highlights

The product segment led the market and accounted for the largest revenue share of 80.9% in 2020 owing to the wide application of miRNA sequencing and assay in healthcare industries. Moreover, key players offer an extensive range of technologically advanced products in this segment. For instance, Illumina Inc. offers an extensive range of library preparation, sequencing instruments, accessories, consumables, and software and informatics for miRNA sequence analysis.

Moreover, ongoing extensive research to develop new products is likely to expand segment market share during the forecast period. For instance, researchers from the Université de Lyon developed BrumiR, an algorithm that can discover miRNAs exclusively and directly from sRNA-seq data. The results demonstrated by this toolkit were found to be much faster and more efficient.

The service segment is anticipated to grow at a lucrative rate in the market throughout the forecast period. Several prominent players offer services in miRNA sequencing and assay. Companies such as Eurofins Genomics, Arraystar Inc., Novogene Co., Ltd., Creative Biolabs, and others offer an extensive workflow for miRNA sequencing and assay.

The Sequencing by Synthesis (SBS) technology segment dominated the microRNA sequencing and assay market and accounted for the largest revenue share of 31.8% in 2020. The large share of the segment is attributed to the ongoing research and study in miRNA sequencing and assay by synthesis. According to a January 2021 study, researchers from Germany, China, and the U.S. evaluated the standard SBS and the approaches used for this. The study established that SBS recovered more annotated miRNAs, and generated more novel miRNAs.

Additionally, SBS technology is widely used to analyze and study several cancers and to develop personalized therapies. This is expected to contribute to a large share of the segment during the forecast period. Sequencing by Oligonucleotide Ligation and Detection (SOLiD) technology is known for its accuracy particularly when the coverage is more than 30x. Hence, it is extensively used in identifying variations in resequencing, transcriptome sequencing, and targeted resequencing. At Present, systems available in the market have 99.99% accuracy and 30 G per run of data output. Therefore, the SOLiD technology segment is anticipated to witness the fastest CAGR over the forecast period.

The sequencing workflow segment dominated the microRNA sequencing and assay market and accounted for the largest revenue share of 53.3% in 2020. Small RNA sequencing is becoming a popular approach to address multiple biological issues associated with the regulation of miRNAs and other small non-coding RNAs. miRNA, piRNA, and siRNA are the three most focused small RNAs and are extensively analyzed by sequencing since they have been identified to play a crucial role in the post-translational regulation of gene expression.

Additionally, sequence analysis helps to identify and analyze a complete range of miRNA and small RNA species. Furthermore, miRNA sequencing and assay also helps identify how post-transcriptional regulation affects phenotype and discover novel biomarkers, which has broad application in complex disease and cancer research. Illumina inc. platforms are the most popular instruments for miRNA sequence analysis, such as MiSeq and HiSeq.

The library preparation segment held the second-largest revenue share in the market in 2020. Companies like GENEWIZ offer library preparation services as a standalone service to customers and accelerate their in-house capabilities. GENEWIZ offers services for sequencing of the amplicon, RNA-Seq, exome, whole-genome, targeted resequencing, and cancer panels.

The cancer segment dominated the market and accounted for the largest revenue share of 36.0% in 2020. Dysregulated miRNAs have been studied as a new type of tumor suppressor gene or oncomiR which are playing important roles in cancer initiation and development. Aberrant expression of miRNAs shows great potential as cancer biomarkers with high sensitivity and specificity.

miRNAs play a crucial role in the regulation of hallmarks of cancer, such as apoptosis, proliferation, invasion, metastasis, and stemness in tumors. Many miRNAs are identified as biomarkers for breast cancer for diagnosis and indicators of prognosis. Furthermore, the active participation of several global organizations, such as the National Cancer Institute, National Foundation for Cancer Research, Cancer Research Institute, and Cancer Research U.K., in cancer research is expected to positively influence the progress of this vertical over the forecast period.

The polyglutamine diseases application segment is expected to register the fastest CAGR over the forecast period. Particular expression patterns of miRNA in the brain parenchyma and circulating fluids and have been identified as potential biomarkers for prognosis and diagnosis of polyglutamine disease.

The research and academic institutes segment dominated the market and accounted for the largest revenue share of 54.9% in 2020. Several academic institutes are taking initiative to accelerate research related to miRNA sequencing and assay. For instance, the University of Manchester researchers have created a database of miRNAs that have become an important resource in academia and the biotechnology industry.

The data empowers the construction of experimental kits and resources that support experimental microRNA research across academic and industrial settings, which ultimately benefits product development, drug discovery, and clinical research. The pharmaceutical and biotechnology industry segment is expected to witness a substantial CAGR over the forecast period. Companies such as Regulus Therapeutics are involved in the development of miRNA-based therapeutics. Rising investments to develop techniques and tools to overcome existing challenges in the clinical translation of miRNA sequencing and assay applications are likely to supplement segment growth.

North America dominated the miRNA sequencing and assay market and accounted for the largest revenue share of 46.1% in 2020. This can be attributed to the local presence of a significant number of key players, such as Illumina Inc., Thermo Fisher Scientific, PerkinElmer, Inc., and others. The increase in research and development spending by major players to develop innovative and advanced products in the U.S. is expected to drive regional growth. For instance, in 2020 Illumina, Inc. spent USD 682 million on research and development to develop new sequence analysis technology and upgrade existing technology.

The presence of several associations and organizations operating in this region that take initiatives to spread awareness about new advanced miRNA sequencing products and technology drive regional growth. Additionally, miRNA sequencing and assay are significantly adopted by clinics, healthcare networks, military, and agriculture laboratories that receive support through government funding. Thus, supportive government laws and investments are contributing to the regional market growth.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38148

Key Market Trends

Library Preparation Kits are Expected to Hold the Largest Market Share in the miRNA Sequencing and Assay Market

The capacity of library preparation kits to shorten the RNA fragmentation process and an increase in research activities relevant to complicated life sciences processes are two main reasons driving the library preparation kits segment. The increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, etc., and rare diseases are increasing the demand for effective treatment options and are propelling the growth of the miRNA market. Moreover, the advancement and adoption of next-generation sequencing methods and their applications in various fields are further boosting the miRNA sequencing market in the forecast period.

For instance, Qiagen’s QIAseq miRNA Library Kit includes gel-free miRNA sequencing library prep from 1 ng of total RNA. It eliminates adapter dimers and undesired RNA species for the greatest fidelity and most effective data, incorporates Unique Molecular Indices (UMIs) for quantitative measurement of individual miRNA molecules, and connects directly to the RNA-seq analysis portal for human, mouse, and rat samples. Hence, with the presence of such advanced kits available in the market, the segment is believed to witness strong growth over the forecast period.

According to the American Cancer Society, an estimated 36,000 new cancer cases occurred in Wisconsin in 2021. According to Rare Disease day, rare diseases are estimated to affect nearly 3.5% - 5.9% of the global population in 2020, with over 300 million people living with one or more of over 6,000 identified rare diseases worldwide. With the rising cancer cases, the use of library preparation kits is increasing which is propelling the segment growth.

Key Players

• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• QIAGEN
• PerkinElmer, Inc.
• Abcam plc
• New England Biolabs
• Takara Bio Inc.
• Lexogen GmbH
• Norgen Biotek Corp
• Maravai LifeSciences
• HTG Molecular Diagnostics, Inc.
• Meridian Bioscience, Inc.
• System Biosciences, LLC

Market Segmentation

• By Product & Service Outlook
  • Products
    • Library Preparation Kits
    • Sequencing Consumables
    • Instruments
  • Services
• By Technology Outlook
  • Sequencing (Seq.) By Synthesis
  • Seq. By Oligonucleotide Ligation and Detection (SOLiD)
  • Nanopore Seq.
  • Sanger Seq.
  • Single Molecule Real-time (SMRT) Seq.
• By Workflow Outlook
  • Library Preparation
  • Sequencing
  • Data Analysis & Storage
• By Application Outlook
  • Cancer
  • Polyglutamine Diseases
  • Autoimmune Disease
  • Schizophrenia
  • Others
• By End-use Outlook
  • Pharmaceutical & Biotechnology Industry
  • Research and Academic Institutes
  • Contract Research Organizations
• By Regional Outlook
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East Africa (MEA)

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38148

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://qyresearchmedical.com/